Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Embecta Corp.NASDAQ: EMBC

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 58.92M shares rose 0.5% year over year, in line with the +0.9% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +1.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +0.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
58.92M+0.0% QoQ
Last fiscal yearSep 2025
58.92M+1.0% YoY
LTMMar 2026
58.8M+0.9% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+1.0%——
3-year CAGR+1.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
58.92M USD
Year-over-year change
+1.0%
4-year CAGR
+0.9%

Weighted Avg Shares (Diluted) vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 weighted avg shares (diluted) of 58.8M shares is the 9th highest of the 11 companies compared; the peer median is 103.52M shares.
  • Its year-over-year change of +0.9% is the 7th highest of 11, against a peer median of +2.5%.
  • Over three fiscal years its annual growth of +1.1% compares with a peer median of +4.6%.
EMBC Competitors Peer median
Weighted Avg Shares (Diluted) for EMBC and competitors
Company Period LTM YoY 3-year CAGR
PRMEPrime Medicine, Inc.LTM Mar 2026153.89M +26.0%+15.2%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+0.9%
EVHEvolent Health, Inc.LTM Mar 2026114.02M -0.8%+6.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
PSNLPersonalis, Inc.LTM Mar 202693.42M +36.5%+25.0%
MYGNMyriad Genetics, Inc.LTM Mar 202693.15M +2.4%+5.0%
SIGASIGA Technologies, Inc.LTM Mar 202671.65M -0.0%-0.9%
EMBCEmbecta Corp.LTM Mar 202658.8M +0.9%+1.1%
EBSEmergent BioSolutions Inc.LTM Mar 202654.9M -0.0%+4.2%
CDNACareDx, IncLTM Jun 202652.85M -4.2%-0.0%
Peer median (excluding EMBC) 103.52M+2.5%+4.6%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.